Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Warry, Emma; Willcox, Jennifer L.; Suter, Steven E.

doi:10.1111/jvim.12302

Cited by 27 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty‐three percent of these dogs lived >2 years post BMT. Our group also treated 15 dogs with T‐cell CL using autologous BMT and reported a median DFI and OS of the 13 dogs transplanted in first remission from the time of BMT as 184 and 240 days, respectively. Two of 13 (15%) dogs were alive 741 and 772 days post BMT.…”

Section: Treatment Of CL and Clinical Trialsmentioning

confidence: 98%

Man's best friend: what can pet dogs teach us about non‐Hodgkin's lymphoma?

Richards

Suter

2014

Immunological Reviews

View full text Add to dashboard Cite

Summary Animal models are essential for understanding lymphoma biology and testing new treatments prior to human studies. Spontaneously arising lymphomas in pet dogs represent an underutilized resource that could be used to complement current mouse lymphoma models, which do not adequately represent all aspects of the human disease. Canine lymphoma resembles human lymphoma in many important ways, including characteristic translocations and molecular abnormalities and similar therapeutic responses to chemotherapy, radiation, and newer targeted therapies (e.g. ibrutinib). Given the large number of pet dogs and high incidence of lymphoma, particularly in susceptible breeds, dogs represent a largely untapped resource for advancing the understanding and treatment of human lymphoma. This review highlights similarities in molecular biology, diagnosis, treatment, and outcomes between human and canine lymphoma. It also describes resources that are currently available to study canine lymphoma, advantages to be gained by exploiting the genetic breed structure in dogs, and current and future challenges and opportunities to take full advantage of this resource for lymphoma studies.

show abstract

Section: Treatment Of CL and Clinical Trialsmentioning

confidence: 98%

Man's best friend: what can pet dogs teach us about non‐Hodgkin's lymphoma?

Richards

Suter

2014

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…The benefit in canine TCL is less clear; a small study showed that autologous transplant added a median of eight months to survival in treated dogs, although toxicity was high and treatment-related mortality was 13 per cent (Warry and others 2014). …”

Section: Treatmentmentioning

confidence: 99%

Treatment of T cell lymphoma in dogs

Moore¹

2016

Veterinary Record

View full text Add to dashboard Cite

Overall, canine lymphoma remains one of the most chemotherapy-responsive cancers in the dog. In addition to the stage and the substage of disease, T cell phenotype is the most consistently important prognostic factor. T cell lymphoma (TCL) in dogs is a heterogeneous disease; dogs with a separate entity of indolent TCL can have a considerably better prognosis than dogs with other forms of lymphoma, and indolent TCL may not always require immediate treatment. In contrast, high-grade TCL is an aggressive disease, and when treated with CHOP-based protocols, dogs with this high-grade TCL have a complete remission rate as low as 40 per cent, relapse earlier and have shorter survival time than dogs with a comparable stage, high-grade B cell lymphoma. This review describes the different disease entities that comprise canine TCL, discusses prognosis for each and treatment options that appear to give the best outcomes.

show abstract

“…High‐dose (8‐12 Gy) TBI protocols are more common in modern veterinary medicine. The most common indications include eradicating the recipient's bone marrow in preparation for an autologous stem cell transplant (SCT) and immunosuppressing the recipient to decrease the chances of allogeneic SCT rejection …”

Section: Introductionmentioning

confidence: 99%

Implementation of total body photon irradiation as part of an institutional bone marrow transplant program for the treatment of canine lymphoma and leukemias

Gieger

Nolan

Roback

et al. 2019

Vet Radiology Ultrasound

View full text Add to dashboard Cite

A total body irradiation (TBI) protocol was developed to support a bone marrow transplant (BMT) program for the treatment of canine hematologic malignancies. The purpose of this prospective study is to describe implementation of the protocol and resultant dosimetry. Nongraphic manual treatment planning using 6 MV photons, isocentric delivery, 40 × 40 cm field size, wall-mounted lasers to verify positioning, a lucite beam spoiler (without use of bolus material), a dose rate of 8.75 cGy/min at patient isocenter, and a source-to-axis distance of 338 cm were used for TBI. A monitor unit calculation formula was derived using ion chamber measurements and a solid water phantom. Five thermoluminescent dosimeters (TLDs) were used at various anatomic locations in each of four cadaver dogs, to verify fidelity of the monitor unit formula prior to clinical implementation. In vivo dosimetric data were then collected with five TLDs at various anatomic locations in six patients treated with TBI. A total dose of 10 Gy divided into two 5 Gy fractions was delivered approximately 16 h apart, immediately followed by autologous stem cell transplant. The mean difference between prescribed and delivered doses ranged from 99% to 109% for various sites in cadavers, and from 83% to 121% in clinical patients. The mean total body dose in cadavers and clinical patients when whole body dose was estimated by averaging doses measured by variably placed TLDs ranged from 98% to 108% and 93% to 102% of the prescribed dose, respectively, which was considered acceptable. This protocol could be used for institutional implementation of TBI. K E Y W O R D Scadaver, lymphosarcoma, myeloablation, thermoluminescent dosimeter 1 586

show abstract

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Cited by 27 publications

References 31 publications

Man's best friend: what can pet dogs teach us about non‐Hodgkin's lymphoma?

Man's best friend: what can pet dogs teach us about non‐Hodgkin's lymphoma?

Treatment of T cell lymphoma in dogs

Implementation of total body photon irradiation as part of an institutional bone marrow transplant program for the treatment of canine lymphoma and leukemias

Contact Info

Product

Resources

About